MEK1 (P124L)
Sign in to save this workspaceMAP2K1 · Variant type: point · HGVS: p.P124L
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Sunitinib | 85.3% | 14.7% | 91.73 |
| 2 | Neratinib | 76.8% | 23.2% | 93.18 |
| 3 | Bosutinib | 72.6% | 27.4% | 87.22 |
| 4 | Pirtobrutinib | 70.8% | 29.2% | 99.49 |
| 5 | Capivasertib | 69.7% | 30.3% | 96.48 |
| 6 | Imatinib | 67.1% | 32.9% | 99.00 |
| 7 | Trametinib | 57.5% | 42.5% | 99.50 |
| 8 | Osimertinib | 57.3% | 42.7% | 97.24 |
| 9 | Fostamatinib | 52.5% | 47.5% | 96.74 |
| 10 | Tivozanib | 50.1% | 49.9% | 92.42 |
| 11 | Vemurafenib | 48.0% | 52.0% | 96.49 |
| 12 | Nintedanib | 46.9% | 53.1% | 90.23 |
| 13 | Gilteritinib | 45.5% | 54.5% | 88.97 |
| 14 | Abrocitinib | 43.9% | 56.1% | 99.50 |
| 15 | Ripretinib | 43.3% | 56.7% | 92.95 |
| 16 | Cabozantinib | 39.4% | 60.6% | 92.73 |
| 17 | Zanubrutinib | 27.0% | 73.0% | 98.24 |
| 18 | Ponatinib | 25.2% | 74.8% | 78.23 |
| 19 | Pacritinib | 23.5% | 76.5% | 88.64 |
| 20 | Lorlatinib | 23.1% | 76.9% | 97.24 |
| 21 | Cobimetinib | 21.2% | 78.8% | 100.00 |
| 22 | Axitinib | 19.6% | 80.4% | 93.23 |
| 23 | Binimetinib | 19.1% | 80.9% | 100.00 |
| 24 | Dasatinib | 18.9% | 81.1% | 87.97 |
| 25 | Defactinib | 17.3% | 82.7% | 92.68 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Sunitinib | 85.3% | 68.7% | +16.7% |
| Neratinib | 76.8% | 74.7% | +2.0% |
| Bosutinib | 72.6% | 89.8% | -17.3% |
| Pirtobrutinib | 70.8% | 81.8% | -11.0% |
| Capivasertib | 69.7% | 45.6% | +24.1% |
| Imatinib | 67.1% | — | — |
| Trametinib | 57.5% | 98.7% | -41.2% |
| Osimertinib | 57.3% | — | — |
| Fostamatinib | 52.5% | — | — |
| Tivozanib | 50.1% | 62.9% | -12.8% |
| Vemurafenib | 48.0% | 77.8% | -29.8% |
| Nintedanib | 46.9% | 46.3% | +0.6% |
| Gilteritinib | 45.5% | 58.6% | -13.0% |
| Abrocitinib | 43.9% | 31.8% | +12.1% |
| Ripretinib | 43.3% | — | — |
| Cabozantinib | 39.4% | 81.2% | -41.8% |
| Zanubrutinib | 27.0% | 54.1% | -27.1% |
| Ponatinib | 25.2% | — | — |
| Pacritinib | 23.5% | 19.3% | +4.2% |
| Lorlatinib | 23.1% | — | — |
| Cobimetinib | 21.2% | 73.5% | -52.3% |
| Axitinib | 19.6% | — | — |
| Binimetinib | 19.1% | 79.1% | -60.0% |
| Dasatinib | 18.9% | 34.5% | -15.6% |
| Defactinib | 17.3% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.7ms